Posted by Michael Wonder on 28 Oct 2025
Cellectar Biosciences receives rare paediatric disease designation from US FDA for iopofosine I 131 in relapsed or refractory paediatric high-grade glioma
27 October 2025 - Cellectar Biosciences today announced the US FDA has granted rare paediatric drug designation for iopofosine I 131 in inoperable relapsed or refractory paediatric high-grade glioma.
Iopofosine I 131 is a potential first in class, novel cancer targeting agent utilising a phospholipid ether as a radioconjugate monotherapy.
